Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | GRK6 | P43250 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL2865953 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2539 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL29946502 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL19063414 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL4810001 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2120833 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2537 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL6550323 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL10477623 | 0.99 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL11688992 | 0.99 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3513782-A1 | GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS | Universita' Degli Studi Di Camerino (IT) | 2019-07-24 | — | — | EP | claimed |
| US-20250367219-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARM INNC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240238315-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARM INNC (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4268897-A2 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | Paratek Pharmaceuticals, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3273968-B1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARM INNC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116392496-A | Minocycline compounds for biological protection | 帕拉特克药品公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230098554-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARM INNC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3812372-A2 | 7-HETEROCYCLYL SUBSTITUTED SANCYCLINE DERIVATIVES FOR TREATING BACTERIAL, VIRAL AND PARASITIC INFECTIONS (E.G. MALARIA) OR INFLAMMATORY DISEASES | Paratek Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3045449-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS | Paratek Pharmaceuticals, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9012433-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2301912-A2 | 4-aminotetracyclines and methods of use thereof | Paratek Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7858601-B2 | 4-substituted tetracyclines and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100305072-A1 | Substituted Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7786099-B2 | Aromatic a-ring derivatives of tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204186-A1 | AROMATIC A-RING DERIVATIVES OF TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-1805134-A2 | 4-AMINOTETRACYCLINES AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060166944-A1 | 4-Aminotetracyclines and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006047671-A2 | 4-AMINOTETRACYCLINES AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060003971-A1 | Aromatic a-ring derivatives of tetracycline compounds | PARATEK PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| CN-1649582-A | Amino-methyl substituted tetracyclines | PARATEK PHARM INNC (US) | 2005-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098554-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885MAPT 1338/4885 |
| US-20060003971-A1 | Aromatic a-ring derivatives of tetracycline compounds | AADAC, TPR, TYMS | TDP1 2214/4885KDM4E 528/4885MAPT 202/4885 |
| US-20060166944-A1 | 4-Aminotetracyclines and methods of use thereof | TET1, TET3, TPT1 | TDP1 1735/4885KDM4E 660/4885MAPT 2233/4885 |
| US-20100204186-A1 | AROMATIC A-RING DERIVATIVES OF TETRACYCLINE COMPOUNDS | AADAC, TPR, TYMS | TDP1 2214/4885KDM4E 528/4885MAPT 202/4885 |
| US-20100305072-A1 | Substituted Tetracycline Compounds | TET1, TET3, MYC | TDP1 2522/4885KDM4E 1193/4885MAPT 815/4885 |
| US-20240238315-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885MAPT 1338/4885 |
| US-20250367219-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885MAPT 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.